Migraine is very common: it affects 15% of European citizens. It is also the most costly neurological disease in the EU, costing more than €27 billion per year. Current medications are only moderately effective. “To develop better drugs, we need to understand how attacks are triggered and become chronic”, says Professor Ferrari.

EUROHEADPAIN consists of ten academic partners and one small to medium-sized enterprise. The consortium originates from several previous collaborations within the field of headache and migraine. Professor van den Maagdenberg: “We will study patients and animal models to identify pathways and molecules involved in migraine.”